Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio) has announced plans to repurchase up to 78.37 million shares—equivalent to 10% of its issued share capital—through on-market transactions, utilising the general mandate granted at the 5 June 2026 annual general meeting.

The board has earmarked a maximum of HK$100.00 million from internal resources to fund the programme. Purchases will be executed at prices no more than 5% above the average closing price of the company’s shares over the five trading days preceding each transaction. The mandate remains valid until the earlier of the next annual general meeting, the deadline prescribed for holding that meeting under Cayman Islands law and the company’s articles, or any revocation or variation of the authority by shareholders.

Jacobio stated that the initiative will not materially affect its working-capital position. Repurchased shares may either be cancelled or held in treasury, and the company will ensure public float requirements under Hong Kong listing rules remain satisfied.

Management cited a belief that the current share price does not fully reflect the value of Jacobio’s oncology R&D pipeline, commercialisation prospects and strong cash reserves. The company highlighted ongoing global clinical trials for multiple targeted anti-tumour therapies and continued inflows from external collaboration agreements as underpinning its healthy liquidity.

The board emphasised that the timing, scale and pricing of any repurchases will depend on market conditions and remain at its sole discretion. Accordingly, shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.